Dario A A Vignali
Overview
Explore the profile of Dario A A Vignali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
196
Citations
19678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li H, Zandberg D, Kulkarni A, Chiosea S, Santos P, Isett B, et al.
Cancer Cell
. 2025 Mar;
PMID: 40086437
We leverage a clinical trial (NCT04080804) that compared neoadjuvant anti-PD-1, anti-PD-1+CTLA-4, and anti-PD-1+LAG-3 therapies in head and neck squamous cell carcinoma patients. Combination therapies promote higher pathologic response rates versus...
2.
Dadey R, Cui J, Rajasundaram D, Yano H, Liu C, Cohen J, et al.
Immunohorizons
. 2025 Feb;
9(4).
PMID: 39965167
Regulatory T cells (Tregs) are a suppressive CD4+ T cell population that limit the antitumor immune response. In this study, we analyzed the chromatin accessibility of Tregs in the murine...
3.
Yang X, Jeong D, Madeo G, Kumbhar R, Wang N, Niu L, et al.
bioRxiv
. 2025 Jan;
PMID: 39803449
Lymphocyte activation gene 3 (LAG3) is a key receptor involved in the propagation of pathological proteins in Parkinson's disease (PD). This study investigates the role of neuronal LAG3 in mediating...
4.
Adam K, Butler S, Workman C, Vignali D
Trends Cancer
. 2024 Nov;
11(1):37-48.
PMID: 39603977
Cancer treatment has entered the age of immunotherapy. Immune checkpoint inhibitor (ICI) therapy has shown robust therapeutic potential in clinical practice, with significant improvements in progression-free survival (PFS) and overall...
5.
Chen F, Onkar S, Zou J, Li Y, Arbore H, Maley S, et al.
NPJ Precis Oncol
. 2024 Nov;
8(1):257.
PMID: 39521942
Understanding interplay of breast cancer and microenvironment is critical. Here we identified two transcriptomic subtypes and five immune infiltration patterns from RNA-seq and multiplex immunohistochemistry from 21 ER + /HER2-...
6.
Nieves-Rosado H, Banerjee H, Gocher-Demske A, Manandhar P, Mehta I, Ezenwa O, et al.
J Immunol
. 2024 Sep;
213(10):1488-1498.
PMID: 39345172
Expression of T cell Ig and mucin domain-containing protein 3 (Tim-3) is upregulated on regulatory T cells (Tregs) during chronic viral infections. In several murine and human chronic infections, the...
7.
Scott E, Ye C, Yano H, Lipatova Z, Brunazzi E, Vignali K, et al.
J Immunol
. 2024 Sep;
213(8):1115-1124.
PMID: 39240167
EBV-induced gene 3 (Ebi3) is a β subunit within the IL-12 cytokine family that canonically binds to α subunits p19, p28, or p35 to form the heterodimeric cytokines IL-39, IL-27,...
8.
Adam K, Lipatova Z, Abdul Ghafoor Raja M, Mishra A, Mariuzza R, Workman C, et al.
J Immunol
. 2024 Aug;
213(7):1043.
PMID: 39158271
No abstract available.
9.
Cillo A, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al.
Cell
. 2024 Aug;
187(16):4373-4388.e15.
PMID: 39121849
Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced melanoma patients received rela, nivo, or rela+nivo...
10.
Andrews L, Butler S, Cui J, Cillo A, Cardello C, Liu C, et al.
Cell
. 2024 Aug;
187(16):4355-4372.e22.
PMID: 39121848
Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) treatment, the first in...